(Q38033468)

27 August 2017

Glucagon-like peptide-1 and its cardiovascular effects (English)

1 reference

27 August 2017

Kyung-Sun Heo

1

1 reference

27 August 2017

Keigi Fujiwara

series ordinal

2

1 reference

27 August 2017

Jun-ichi Abe

series ordinal

3

1 reference

27 August 2017

1 October 2012

1 reference

Current Atherosclerosis Reports

27 August 2017

1 reference

27 August 2017

14

1 reference

27 August 2017

5

1 reference

27 August 2017

422-428

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-012-0265-9

27 August 2017

0 references

cites work

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Glucagon-like peptide-1 (GLP-1) attenuates post-resuscitation myocardial microcirculatory dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Cardiac function in mice lacking the glucagon-like peptide-1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Cloning and expression of a human glucagon receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

International Union of Pharmacology. XXXV. The glucagon receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: incretins: concept and physiological functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

GIP: no longer the neglected incretin twin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Incretin-based therapies for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

The glucagon-like peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Possible involvement of GLP-1(9-36) in the regional haemodynamic effects of GLP-1(7-36) in conscious rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Cell death in the pathogenesis of heart disease: mechanisms and significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Cardiac metabolism in myocardial ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Myocardial reperfusion injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Granulocyte colony-stimulating factor treatment plus dipeptidylpeptidase-IV inhibition augments myocardial regeneration in mice expressing cyclin D2 in adult cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Gastric inhibitory polypeptide receptor, a member of the secretin- vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0265-9

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

21 January 2018

1 reference

12 December 2020

Identification and Actions of Gastric Inhibitory Polypeptide

1 reference

12 December 2020

Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas

1 reference

12 December 2020

Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride

1 reference

12 December 2020

Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain

1 reference

12 December 2020

Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable

1 reference

12 December 2020

Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor.

1 reference

12 December 2020

Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines

1 reference

12 December 2020

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

1 reference

12 December 2020

Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting

1 reference

12 December 2020

10.1007/S11883-012-0265-9

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

0 references

1 reference